Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Protein > Glypican 3 > GP3-HF258

FITC-Labeled Human Glypican 3 / GPC3 Protein, Fc Tag

Order Now

  • Synonym
    GPC3,OCI5,Glypican-3,GTR2-2,MXR7,DGSX,SDYS ,SGB,SGBS,SGBS1
  • Source
    FITC-Labeled Human Glypican 3, Fc Tag (Cat. No. GP3-HF258) is expressed from human HEK293 cells. It contains AA Gln 25 - His 559 (Accession # P51654-1). It is the FITC labeled form of Human Glypican 3, Fc Tag (Cat. No. GP3-H5258).
    Predicted N-terminus: Gln 25 & Ser 359
  • Molecular Characterization
    Online(Gln 25 - His 559) P51654-1

    This protein carries a human IgG1 Fc tag at the C-terminus. This protein contains a furin-like convertase cleavage site, 355-RQYR-358, and will be partially processed into N and C-terminal fragment with calculated MW of 38.1 kDa and 49.3 kDa respectively. The protein migrates as 40 kDa, 60 kDa and 87-120 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Conjugate

    FITC

    Excitation source: 488 nm spectral line, argon-ion laser

    Excitation Wavelength: 488 nm

    Emission Wavelength: 535 nm

  • Labeling
    The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular sieve treatment during purification process.
  • FITC:Protein Ratio
    The FITC to protein molar ratio is 3-5.
  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
FITC-Labeled Human Glypican 3, Fc Tag (Cat. No. GP3-HF258) SDS-PAGE gel

FITC-Labeled Human Glypican 3, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

Bioactivity-ELISA
FITC-Labeled Human Glypican 3, Fc TagFITC-Labeled Human Glypican 3, Fc Tag (Cat. No. GP3-HF258) ELISA bioactivity

Immobilized Anti-Human GPC3 MAb at 10 μg/mL (100 μL/well) can bind FITC-Labeled Human Glypican 3, Fc Tag (Cat. No. GP3-HF258) with a linear range of 0.078-1.25 μg/mL (Ex.488 nm/Em.535 nm) (QC tested).

Bioactivity-FACS
FACS assay shows that recombinant Biotinylated FACS

2e5 of Anti-Glypican 3 CAR-293 cells were stained with 100 μL of 3 μg/mL of FITC-Labeled Human Glypican 3, Fc Tag (Cat. No. GP3-HF258) and negative control protein respectively. FITC signal was used to evaluate the binding activity (QC tested).

  • Background
    Glypican-3 (GPC3) is also known as Intestinal protein OCI-5, GTR2-2, MXR7, which belongs to the glypican family. Glypican 3 / GPC-3 is highly expressed in lung, liver and kidney. Glypican-3 inhibits the dipeptidyl peptidase activity of DPP4. Glypican-3 may be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs, and also may play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)


ETD of in-stock products: 2 business days

Price(USD) : $335.00

Price(USD) : $2289.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:36 Details
  • Latest Research Phase:Phase 2 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message